ScoreWhy is Venmax Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0.21%
- Poor long term growth as Net Sales has grown by an annual rate of 200.30% and Operating profit at 10.45% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0.81 times
2
Flat results in Jun 26
3
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 01-Jun-26 and has generated -32.18% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
With ROE of 1.9, it has a Very Expensive valuation with a 1.5 Price to Book Value
- Over the past year, while the stock has generated a return of -37.83%, its profits have risen by 26% ; the PEG ratio of the company is 0.1
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 0.64% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -37.83% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Venmax Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Venmax Drugs
-27.86%
-0.61
62.21%
Sensex
-11.8%
-0.48
13.44%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
200.30%
EBIT Growth (5y)
10.45%
EBIT to Interest (avg)
-0.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.36
Tax Ratio
9.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-1.55%
ROE (avg)
0.46%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
74
Industry P/E
36
Price to Book Value
1.39
EV to EBIT
20.25
EV to EBITDA
20.25
EV to Capital Employed
1.41
EV to Sales
2.18
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
1.04%
ROE (Latest)
1.87%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
DEBTORS TURNOVER RATIO(HY)
Highest at 5.77 times
PBDIT(Q)
Highest at Rs 0.12 cr.
PBT LESS OI(Q)
Highest at Rs 0.12 cr.
PAT(Q)
Highest at Rs 0.12 cr.
EPS(Q)
Highest at Rs 0.10
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Venmax Drugs
Operating Profit (PBDIT) - Quarterly
Highest at Rs 0.12 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.12 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.12 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.10
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Debtors Turnover Ratio- Half Yearly
Highest at 5.77 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
